London Daily

Focus on the big picture.
Thursday, Oct 30, 2025

Covid-19: Novavax vaccine shows 89% efficacy in UK trials

Covid-19: Novavax vaccine shows 89% efficacy in UK trials

A new coronavirus vaccine has been shown to be 89% effective in large-scale UK trials.

The Novavax jab is the first to show in trials that it is effective against the new virus variant found in the UK, the BBC's medical editor Fergus Walsh said.

The UK has secured 60 million doses of the jab, which will be made in Stockton-on-Tees in north-east England.

Meanwhile, a single-dose vaccine developed by Janssen is 66% effective, trial results have shown.

Janssen, a company owned by Johnson & Johnson, is also investigating whether giving two doses will give either stronger or longer-lasting protection.

The company said its initial findings showed one dose prevented 85% of severe cases.

Both the Novavax and Janssen jabs will need to be reviewed by regulators before they can be used.

The PM welcomed the "good news", with doses of the Novavax jab expected to be delivered in the second half of this year if approved for use by the Medicines and Healthcare Products Regulatory Agency (MHRA), the government said.

The UK has so far approved three coronavirus vaccines for emergency use - one from Oxford University and AstraZeneca, another by Pfizer and BioNTech, and a third from drug firm Moderna.

The Novavax jab, which is given in two doses, was shown to be 89.3% effective at preventing Covid-19 in participants in its Phase 3 clinical trial in the UK, and around 86% effective at protecting against the new UK variant. The jab's efficacy against the original Covid-19 strain was calculated to be 95.6%.

The Phase 3 trials - the final stage before a vaccine is looked at by a regulator - enrolled more than 15,000 people aged between 18-84, of whom 27% were older than 65, US firm Novavax said.

In the South African part of the trial, where most of the cases were the South African variant of the virus, the vaccine was 60% effective among those without HIV.

Stan Erck, chief executive of Novavax, said the results from the UK trial were "spectacular" and "as good as we could have hoped", while the efficacy in South Africa was "above people's expectations".

He told the BBC the manufacturing plant in Stockton-on-Tees should be up and running by March or April, with the company hoping to get approval for the vaccine from the MHRA around the same time.

Minister Lucy Frazer told BBC Breakfast the government could not put an exact timeframe on when the Novavax jab might be approved as the regulation process is "out of our control".

Health Secretary Matt Hancock said the new vaccine would be "another weapon in our arsenal to beat this awful virus", if approved.

Prof Paul Heath, chief investigator of the UK Novavax trial, said the trial findings were "enormously exciting", particularly because of the jab's efficacy against the UK variant.



These extremely encouraging trial results suggest another powerful vaccine against coronavirus could soon be within reach.

It works in a slightly different way to the ones that are already available - but does the same job of teaching the body's immune system to recognise and fight the pandemic virus.

What is more, it appears to be effective against emerging and more infectious variants of coronavirus too - something scientists have feared might not be possible because the vaccines were all designed to match the original virus, not these new, mutated versions.

Protection against illness from the new UK variant was high - around 86%.

Even with the South Africa variant, which has undergone the most worrisome changes, it offered a level of protection similar to that given by flu shots against influenza.

England's chief medical officer Prof Chris Whitty said, if the jab is approved, it "increases our future resilience" against the virus.

Nadhim Zahawi, the UK minister responsible for the vaccine rollout, said he was "particularly thrilled" to see the positive results as he had taken part in Novavax's trials himself.

In total, the UK has ordered 100 million doses of the Oxford-AstraZeneca vaccine and 40 million of the Pfizer-BioNTech vaccine - both are currently being rolled out in the UK.

Another 17 million doses of the Moderna vaccine, which was approved by the MHRA in early January, are expected in the spring.

The aim is to give everyone in the top four priority groups - up to 15 million people - a first dose by mid-February.

Pfizer and Moderna vaccines rely on technology that has not been used in previous vaccines, but the Novavax jab uses a more traditional method of recreating part of the spike protein of the virus to stimulate the immune system.

Like the Oxford vaccine, the Novavax jab can be stored at regular fridge temperature - which means it can be distributed more easily.



More than 7.4 million people in the UK have so far received a first dose of a coronavirus vaccine, according to the latest government figures.

Meanwhile, the latest estimate for the UK's R rate from the government's scientific advisory group, Sage, is 0.7 to 1.1. It means that on average, every 10 people with the virus will infect between seven and 11 other people. Last week, the R rate was between 0.8 and 1.

The latest growth rate range is between -5% and 0%, indicating that the number of new infections is broadly flat or shrinking by up to 5% every day.

Separately, the EU's vaccine contract with AstraZeneca has been published, in a growing row over reduced supplies of their jab.

Kate Bingham, who used to chair the UK's Vaccine Taskforce, said the reason the UK had a good supply of vaccines compared with other countries was because of its ability to get clinical trials completed quickly and at a high standard through the NHS's registry - with some 400,000 volunteers signing up "before the US even started their Phase 3 studies".

The UK recorded a further 1,239 deaths within 28 days of a positive coronavirus test on Thursday. There have also been another 28,680 new infections.


Novavax chief executive: UK trial results are "spectacular"


Newsletter

Related Articles

0:00
0:00
Close
UK and Vietnam Sign Landmark Migration Deal to Fast-Track Returns of Irregular Arrivals
UK Drug-Pricing Overhaul Essential for Life-Sciences Ambition, Says GSK Chief
Princesses Beatrice and Eugenie Temporarily Leave the UK Amid Their Parents’ Royal Fallout
UK Weighs Early End to Oil and Gas Windfall Tax as Reeves Seeks Investment Commitments
UK Retail Inflation Slows as Shop Prices Fall for First Time Since Spring
Next Raises Full-Year Profit Guidance After Strong Third-Quarter Performance
Reform UK’s Lee Anderson Admits to 'Gaming' Benefits System While Advocating Crackdown
United States and South Korea Conclude Major Trade Accord Worth $350 Billion
Hurricane Melissa Strikes Cuba After Devastating Jamaica With Record Winds
Vice President Vance to Headline Turning Point USA Campus Event at Ole Miss
U.S. Targets Maritime Narco-Routes While Border Pressure to Mexico Remains Limited
Bill Gates at 70: “I Have a Real Fear of Artificial Intelligence – and Also Regret”
Elon Musk Unveils Grokipedia: An AI-Driven Alternative to Wikipedia
Saudi Arabia Unveils Vision for First-Ever "Sky Stadium" Suspended Over Desert Floor
Amazon Announces 14 000 Corporate Job Cuts as AI Investment Accelerates
UK Shop Prices Fall for First Time Since March, Food Leads the Decline
London Stock Exchange Group ADR (LNSTY) Earns Zacks Rank #1 Upgrade on Rising Earnings Outlook
Soap legend Tony Adams, long-time star of Crossroads, dies at 84
Rachel Reeves Signals Tax Increases Ahead of November Budget Amid £20-50 Billion Fiscal Gap
NatWest Past Gains of 314% Spotlight Opportunity — But Some Key Risks Remain
UK Launches ‘Golden Age’ of Nuclear with £38 Billion Sizewell C Approval
UK Announces £1.08 Billion Budget for Offshore Wind Auction to Boost 2030 Capacity
UK Seeks Steel Alliance with EU and US to Counter China’s Over-Capacity
UK Struggles to Balance China as Both Strategic Threat and Valued Trading Partner
Argentina’s Markets Surge as Milei’s Party Secures Major Win
British Journalist Sami Hamdi Detained by U.S. Authorities After Visa Revocation Amid Israel-Gaza Commentary
King Charles Unveils UK’s First LGBT+ Armed Forces Memorial at National Memorial Arboretum
At ninety-two and re-elected: Paul Biya secures eighth term in Cameroon amid unrest
Racist Incidents Against UK Nurses Surge by 55%
UK Chancellor Rachel Reeves Cites Shared Concerns With Trump Administration as Foundation for Early US-UK Trade Deal
Essentra plc: A Closer Look at a UK ‘Penny Stock’ Opportunity Amid Market Weakness
U.S. and China Near Deal to Avert Rare-Earth Export Controls Ahead of Trump-Xi Summit
Justin time: Justin Herbert Shields Madison Beer with Impressive Reflex at Lakers Game
Russia’s President Putin Declares Burevestnik Nuclear Cruise Missile Ready for Deployment
Giuffre’s Memoir Alleges Maxwell Claimed Sexual Act with Clooney
House Republicans Move to Strip NYC Mayoral Front-Runner Zohran Mamdani of U.S. Citizenship
Record-High Spoiled Ballots Signal Voter Discontent in Ireland’s 2025 Presidential Election
Philippines’ Taal Volcano Erupts Overnight with 2.4 km Ash Plume
Albania’s Virtual AI 'Minister' Diella Set to 'Birth' Eighty-Three Digital Assistants for MPs
Tesla Unveils Vision for Optimus V3 as ‘Biggest Product of All Time’, Including Surgical Capabilities
Francis Ford Coppola Auctions Luxury Watches After Self-Financed Film Flop
Convicted Sex Offender Mistakenly Freed by UK Prison Service Arrested in London
United States and China Begin Constructive Trade Negotiations Ahead of Trump–Xi Summit
U.S. Treasury Sanctions Colombia’s President Gustavo Petro over Drug-Trafficking Allegations
Miss USA Crowns Nebraska’s Audrey Eckert Amid Leadership Overhaul
‘I Am Not Done’: Kamala Harris Signals Possible 2028 White House Run
NBA Faces Integrity Crisis After Mass Arrests in Gambling Scandal
Swift Heist at the Louvre Sees Eight French Crown Jewels Stolen in Under Seven Minutes
U.S. Halts Trade Talks with Canada After Ontario Ad Using Reagan Voice Triggers Diplomatic Fallout
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
×